Abstract
Over the last few decades it has been shown that novel technologies and technological progress rapidly change the working environment of radiologists and nuclear medicine physicians. Thus, new possibilities, e.g., in tumor staging and therapy monitoring, but also new challenges arise. Recently, it could be shown that the integration of magnetic resonance imaging (MRI) and positron emission tomography (PET) is technically possible. The evolvement of new dedicated hybrid MR/PET systems for whole-body imaging in humans offers new potential in multimodal imaging. Especially simultaneous measurement of PET and MRI datasets allows for insights in metabolic and functional processes, particularly in oncologic demands, but also in cardiovascular and cerebral imaging. In this work-in-progress review article, a technical summary including the method-inherent challenges are given. Furthermore, possible clinical applications and research interests are addressed.
Similar content being viewed by others
References
Catana C, Procissi D, Wu Y, et al. (2008) Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci USA 105:3705–3710
Judenhofer MS, Wehrl HF, Newport DF, et al. (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459–465
Pichler BJ, Judenhofer MS, Catana C, et al. (2006) Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 47:639–647
Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ (2009) Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 36(Suppl 1):S56–S68
Schlemmer HP, Pichler BJ, Schmand M, et al. (2008) Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248:1028–1035
Bisdas S, Nagele T, Schlemmer HP, et al. (2010) Switching on the lights for real-time multimodality tumor neuroimaging: The integrated positron-emission tomography/MR imaging system. AJNR Am J Neuroradiol 31:610–614
Boss A, Bisdas S, Kolb A, et al. (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51:1198–1205
Boss A, Kolb A, Hofmann M, et al. (2010) Diffusion tensor imaging in a human PET/MR hybrid system. Invest Radiol 45:270–274
Boss A, Stegger L, Bisdas S, et al. (2011) Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol 21(7):1439–1446
Schlemmer HP, Pichler BJ, Krieg R, Heiss WD (2009) An integrated MR/PET system: prospective applications. Abdom Imaging 34:668–674
Pichler BJ, Wehrl HF, Judenhofer MS (2008) Latest advances in molecular imaging instrumentation. J Nucl Med 49(Suppl 2):5S–23S
Kolb A, Lorenz E, Judenhofer MS, et al. (2010) Evaluation of Geiger-mode APDs for PET block detector designs. Phys Med Biol 55:1815–1832
Pichler B, Lorenz E, Mirzoyan R, et al. (1997) Performance test of a LSO-APD PET module in a 9.4 Tesla magnet. IEEE Nucl Sci Symp 2:1237–1239
Probst S, Seltzer A, Spieler B, Chachoua A, Friedman K (2011) The appearance of cardiac metastasis from squamous cell carcinoma of the lung on F-18 FDG PET/CT and post hoc PET/MRI. Clin Nucl Med 36:311–312
Small GR, Ruddy TD (2011) PET imaging of aortic atherosclerosis: Is combined imaging of plaque anatomy and function an amaranthine quest or conceivable reality? J Nucl Cardiol 18:717–728
Vermeltfoort IA, Raijmakers PG, Lubberink M, et al. (2011) Feasibility of subendocardial and subepicardial myocardial perfusion measurements in healthy normals with (15)O-labeled water and positron emission tomography. J Nucl Cardiol 18:650–656
Ewelt C, Floeth FW, Felsberg J, et al. (2011) Finding the anaplastic focus in diffuse gliomas: The value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113:541–547
Makino K, Hirai T, Nakamura H, et al. (2011) Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med 25:432–438
Rottenburger C, Hentschel M, Kelly T, et al. (2011) Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med 36:639–642
Padhani AR, Krohn KA, Lewis JS, Alber M (2007) Imaging oxygenation of human tumours. Eur Radiol 17:861–872
Cai W, Chen K, Mohamedali KA, et al. (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47:2048–2056
Chen K, Cai W, Li ZB, Wang H, Chen X (2009) Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol 11:15–22
Sorensen M, Frisch K, Bender D, Keiding S (2011) The potential use of 2-[(18)F]fluoro-2-deoxy-d:-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 38:1723–1731
Coombs BD, Szumowski J, Coshow W (1997) Two-point Dixon technique for water-fat signal decomposition with B0 inhomogeneity correction. Magn Reson Med 38:884–889
Martinez-Moller A, Souvatzoglou M, Delso G, et al. (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 50:520–526
Hofmann M, Steinke F, Scheel V, et al. (2008) MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med 49:1875–1883
Hofmann M, Bezrukov I (2011) MR-based attenuation correction for whole-body PET/MR—quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med 52:1392–1399
Kitajima K, Nakamoto Y, Okizuka H, et al. (2008) Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 22:595–602
Dellestable P, Granel-Brocard F, Rat AC, et al. (2011) Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT. Ann Dermatol Venereol 138:377–383
Aukema TS, Olmos RA, Korse CM, et al. (2010) Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 17:1657–1661
Pfannenberg C, Aschoff P, Schanz S, et al. (2007) Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43:557–564
Punwani S, Taylor SA, Bainbridge A, et al. (2010) Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 255:182–190
Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al. (2011) Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma—a pilot study: comparison with 2-deoxy-2-fluoro-d-glucose-positron emission tomography/computed tomography. NMR Biomed. doi:10.1002/nbm.1689
van Ufford HM, Kwee TC, Beek FJ, et al. (2011) Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol 196:662–669
Lutje S, de Rooy JW, Croockewit S, et al. (2009) Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 88:1161–1168
Lin C, Luciani A, Itti E, Haioun C, Rahmouni A (2007) Whole body MRI and PET/CT in haematological malignancies. Cancer Imaging 7 Spec No A:S88–S93
Shortt CP, Gleeson TG, Breen KA, et al. (2009) Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 192:980–986
Heusner T, Golitz P, Hamami M, et al. (2011) “One-stop-shop” staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? Eur J Radiol 78:430–435
Takenaka D, Ohno Y, Matsumoto K, et al. (2009) Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30:298–308
Luboldt W, Kufer R, Blumstein N, et al. (2008) Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 249:1017–1025
Eschmann SM, Pfannenberg AC, Rieger A, et al. (2007) Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 46:161–168 (quiz N147-168)
Yi CA, Shin KM, Lee KS, et al. (2008) Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248:632–642
Ohno Y, Koyama H, Onishi Y, et al. (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment–utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248:643–654
Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ (2006) Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 11:58–65
Ambrosini V, Campana D, Bodei L, et al. (2010) 68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669–673
Mayo SC, de Jong MC, Bloomston M, et al. (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. doi:10.1245/s10434-011-1832-y
Ruf J, Heuck F, Schiefer J, et al. (2010) Impact of Multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91:101–109
Sarmiento JM, Que FG (2003) Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12:231–242
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schwenzer, N.F., Schmidt, H. & Claussen, C.D. Whole-body MR/PET: applications in abdominal imaging. Abdom Imaging 37, 20–28 (2012). https://doi.org/10.1007/s00261-011-9809-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-011-9809-7